Biogen Idec 1Q
1Q Revenues: $1.0 billion (+10%)
1Q Earnings: $244 million (+50%)
Comments: Growth was driven by Tysabri sales up 44% to $165 million, Rituxan sales through the company's partnership with Genentech were up 13% to $279 million, and Avonex sales were up 4% to $555 million. Global sales of Tysabri, co-promoted with Elan Corp., were $227 million, of which $116 million was in the U.S. and $111 million ROW.